Masha Maharaj
Umhlanga Molecular Imaging and Therapy Centre, South Africa
Posters & Accepted Abstracts: J Nucl Med Radiat Ther
Nuclear Physician Specialist, Umhlanga Molecular Imaging and Therapy Centre Personalized medicine has shifted the paradigm of individualized patient management in evidence-based medicine. In the last 2 decades, advances in targeted radiotherapy have set the stage for a new group of targeting agents with promising performances. Specific imaging probes are the nuclear fuel for molecular imaging by Single Photon Emission Tomography (SPECT) or Positron Emission Tomography (PET). The non-invasive depiction and quantification of biochemical processes with the goal of functional characterization of tumor biology is critical toward the understanding of tumour behaviour. Interpreting and translating these imaging targets into targeting therapeutic agents (Theranostics) is fundamental in selecting alternative therapy options, predicting response in therapy and estimating therapeutic outcome, thus personalizing therapy on a molecular level. There has been increasing weight placed upon quantification of quality of life in the individual. Generally these agents are well tolerated without serious side effects. This has widened the impact and outcome of target radiotherapy and generated the theranostics era.
Email: drmasha@yahoo.co.uk
Nuclear Medicine & Radiation Therapy received 706 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 